Dr. Charles Theuer has been President, CEO, and a Board Director of TRACON Pharmaceuticals (NASDAQ: TCON) since 2006. Prior thereto, Theuer was Chief Medical Officer at TargeGen Inc., where he initiated the development of small molecule kinase inhibitors in oncology (including Inrebic®, a JAK2 inhibitor approved for myelofibrosis), ophthalmology and cardiovascular disease. At Pfizer, Theuer was a Director of Clinical Oncology and led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in January 2006 for treating advanced kidney cancer. Prior thereto, Theuer held senior positions at IDEC Pharmaceuticals and the National Cancer Institute (NCI) developing other agents, including small molecules and monoclonal antibody therapies.
Theuer holds a BS degree from the Massachusetts Institute of Technology, an M.D. degree from the University of California, San Francisco and a PhD degree from the University of California, Irvine (UCI). He completed a residency in general surgery at Harbor-UCLA Medical Center and was Board Certified in general surgery in 1997.
Theuer held academic positions at the NCI and at UCI, where he was a member of the Division of Surgical Oncology and Department of Medicine. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, as well as gastro-intestinal cancer epidemiology. He also serves as a Board Director at 4D Molecular Therapeutics (Emeryville, CA), and Oncternal Therapeutics (NASDAQ: ONCT).